BLUEROCK
Clinical Trials

Clinical trials are a critical component to investigate potential new medicines in people with a particular disease or condition. These trials rely on patients like you to determine whether an investigational medicine is safe and effective.

Learn more about the clinical trials being led by 午夜寻花, including opportunities for how to get involved.

See Actively Recruiting Trials

Actively Recruiting Trials

Ophthalmology | Primary photoreceptor disease
Active, Recruiting

CLARICO | Primary photoreceptor disease

CLARICO is a clinical study testing a potential new cell therapy for people with certain eye diseases, like retinitis pigmentosa, Usher syndrome, and cone-rod disease. The potential treatment aims to replace damaged eye cells to potentially restore vision.

You may be able to take part in the CLARICO study if you:

  • are 18 years old or older
  • have a primary photoreceptor disease
  • live in the United States or Puerto Rico

Each clinical study has its own guidelines for who can participate. Visit the clinical study website and complete the checklist to see if you pre-qualify.

Trial ID:
Neurology
Active, Recruiting

exPDite-2 | Parkinson’s disease

exPDite-2 is a clinical study evaluating the efficacy and safety of bemdaneprocel, a potential new cell therapy treatment for Parkinson’s disease. Bemdaneprocel is designed to potentially replace the dopamine-producing neurons that are lost in Parkinson’s disease with the aim of engrafting (meaning integrate) into the brain to restore lost function.

You may be considered for exPDite-2 if you:

  • were diagnosed with Parkinson’s disease 4-12 years ago
  • are 45-75 years old
  • are taking levodopa-based treatment to control motor symptoms
  • have at least 2.5 hours of OFF time each day

Each clinical study has its own guidelines for who can participate. Visit the clinical study website and complete the checklist to see if you qualify.

Trial ID:

Active Trials, Not Recruiting

Neurology
Active, Not Recruiting

Noninterventional Study | Parkinson’s disease

This study aims to evaluate the impact, reliability, and consistent use of the Parkinson’s diary to track symptoms when medications do not provide adequate control of symptoms.
Trial ID:
Neurology
Active, Not Recruiting

exPDite | Parkinson’s disease

exPDite was a clinical study designed to evaluate the safety and tolerability of bemdaneprocel, a potential new cell therapy treatment for Parkinson’s disease. The aim was to see if new dopamine-producing neurons could be surgically placed into the brains of people with Parkinson’s disease.
Trial ID:

An expanded access program (also known as EAP) and sometimes called “compassionate use” is a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational drug for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. These investigational drugs have not yet been approved or cleared by regulatory bodies like the FDA, and these products have not yet been found to be safe and effective for their specific use.

We understand that some healthcare professionals may wish to access our investigational drugs for certain patients. At this stage of development and clinical trials for our cell therapies, 午夜寻花 is unable to support expanded access. Therefore, 午夜寻花 Therapeutics does not currently offer an expanded access or a compassionate use program at this time.

This policy may be revised from time to time. Please refer back to this webpage for the most current policy. The most appropriate way for patients to access our investigational drugs is by participating in our clinical trials. If you would like to know more about our ongoing clinical trials, visit .